278 related articles for article (PubMed ID: 2571712)
21. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
[TBL] [Abstract][Full Text] [Related]
22. Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats.
Shannon HE; Hart JC; Bymaster FP; Calligaro DO; DeLapp NW; Mitch CH; Ward JS; Fink-Jensen A; Sauerberg P; Jeppesen L; Sheardown MJ; Swedberg MD
J Pharmacol Exp Ther; 1999 Aug; 290(2):901-7. PubMed ID: 10411607
[TBL] [Abstract][Full Text] [Related]
23. Substituted ergolines: potential antipsychotics with unique profile. I. Psychopharmacological characterization.
Groó D; Palosi A
Pol J Pharmacol Pharm; 1988; 40(6):593-601. PubMed ID: 2908363
[TBL] [Abstract][Full Text] [Related]
24. PNU-96415E, a potential antipsychotic agent with clozapine-like pharmacological properties.
Tang AH; Franklin SR; Himes CS; Smith MW; Tenbrink RE
J Pharmacol Exp Ther; 1997 Apr; 281(1):440-7. PubMed ID: 9103528
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
DeWald HA; Beeson NW; Hershenson FM; Wise LD; Downs DA; Heffner TG; Coughenour LL; Pugsley TA
J Med Chem; 1988 Feb; 31(2):454-61. PubMed ID: 2892936
[TBL] [Abstract][Full Text] [Related]
26. Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery.
Samaha AN; Reckless GE; Seeman P; Diwan M; Nobrega JN; Kapur S
Biol Psychiatry; 2008 Jul; 64(2):145-52. PubMed ID: 18295747
[TBL] [Abstract][Full Text] [Related]
27. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
[TBL] [Abstract][Full Text] [Related]
28. (5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(2-fluorophenyl)methanones . A series of novel potential antipsychotic agents.
Wise LD; Butler DE; DeWald HA; Lustgarten D; Coughenour LL; Downs DA; Heffner TG; Pugsley TA
J Med Chem; 1986 Sep; 29(9):1628-37. PubMed ID: 2875184
[TBL] [Abstract][Full Text] [Related]
29. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects.
Millan MJ; Loiseau F; Dekeyne A; Gobert A; Flik G; Cremers TI; Rivet JM; Sicard D; Billiras R; Brocco M
J Pharmacol Exp Ther; 2008 Mar; 324(3):1212-26. PubMed ID: 18096759
[TBL] [Abstract][Full Text] [Related]
30. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent.
Szewczak MR; Corbett R; Rush DK; Wilmot CA; Conway PG; Strupczewski JT; Cornfeldt M
J Pharmacol Exp Ther; 1995 Sep; 274(3):1404-13. PubMed ID: 7562515
[TBL] [Abstract][Full Text] [Related]
31. Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: a comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs.
Megens AA; Hendrickx HM; Hens KA; Fonteyn I; Langlois X; Lenaerts I; Somers MV; de Boer P; Vanhoof G
J Pharmacol Exp Ther; 2014 Apr; 349(1):138-54. PubMed ID: 24421319
[TBL] [Abstract][Full Text] [Related]
32. [Neuroleptic-like activity of the tripeptide neurotensin analog GZR-123].
Guzevatykh LS; Ostrovskaia RU; Gudasheva TA; Zaĭtseva NI; Voronina TA
Eksp Klin Farmakol; 2002; 65(1):3-6. PubMed ID: 12025780
[TBL] [Abstract][Full Text] [Related]
33. Effects of yohimbine on dopamine dependent behaviours in rats and mice.
Bende MM; Bapat TR; Balsara JJ; Chandorkar AG
Indian J Physiol Pharmacol; 1990 Jul; 34(3):195-200. PubMed ID: 2286423
[TBL] [Abstract][Full Text] [Related]
34. Is dopamine antagonism a requisite of neuroleptic activity?
Greenblatt EN; Coupet J; Rauh E; Szucs-Myers VA
Arch Int Pharmacodyn Ther; 1980 Nov; 248(1):105-19. PubMed ID: 6111298
[TBL] [Abstract][Full Text] [Related]
35. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
[TBL] [Abstract][Full Text] [Related]
36. Some central effects of opioid antagonists. Part I.
Skorupska M; Langwiński R
Pol J Pharmacol Pharm; 1989; 41(5):401-11. PubMed ID: 2577060
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.
Oka M; Noda Y; Ochi Y; Furukawa K; Une T; Kurumiya S; Hino K; Karasawa T
J Pharmacol Exp Ther; 1993 Jan; 264(1):158-65. PubMed ID: 8093723
[TBL] [Abstract][Full Text] [Related]
38. Behavioral effects of cocaine: interactions with D1 dopaminergic antagonists and agonists in mice and squirrel monkeys.
Katz JL; Kopajtic TA; Myers KA; Mitkus RJ; Chider M
J Pharmacol Exp Ther; 1999 Oct; 291(1):265-79. PubMed ID: 10490913
[TBL] [Abstract][Full Text] [Related]
39. FCE 23884, substrate-dependent interaction with the dopaminergic system. I. Preclinical behavioral studies.
Buonamici M; Mantegani S; Cervini MA; Maj R; Rossi AC; Caccia C; Carfagna N; Carminati P; Fariello RG
J Pharmacol Exp Ther; 1991 Oct; 259(1):345-55. PubMed ID: 1681087
[TBL] [Abstract][Full Text] [Related]
40. BMY-14802, a sigma ligand and potential antipsychotic drug, reverses amphetamine-induced changes in neostriatal single-unit activity in freely moving rats.
Wang Z; Haracz JL; Rebec GV
Synapse; 1992 Dec; 12(4):312-21. PubMed ID: 1361249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
